adjuvant composition B

Adjuvant composition B is a novel tolerogenic adjuvant composition developed as a Treg-inducing vaccine for the treatment of Alzheimer's disease (AD). It aims to re-establish immune homeostasis by restoring regulatory T cell (Treg) activity, which is often impaired in AD. In preclinical studies, adjuvant composition B demonstrated superior efficacy compared to a control and another adjuvant composition, mitigating cognitive decline by approximately 40% and reducing amyloid-beta (Aβ) deposition by approximately 30% in immunized mice. Its mechanism involves a substantial increase (approximately 7-fold) in the ratio of Tregs to effector T cells (Teffs) and modulation of neuroinflammatory markers like tumor necrosis factor-alpha and interleukin-6.